• Saved

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33683917/

doi: 10.1200/JCO.20.03433. Online ahead of print. 1 The University of Texas MD Anderson Cancer Center, Houston, TX. 2 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland. 3 Levine Cancer Institute, Atrium Health, Charlotte, NC. 4 Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy. 5 Department of Health Sciences, University of Milan, Milan, Italy.

  • April 25, 2021
    In cross trial comparison this pi3k inhibitor appears to have less toxicity than its predecessors ...will be nice to see if randomized comparative data emerged to prove this